SOURCE: BioDrain Medical Inc.

BioDrain Medical Inc.

August 22, 2011 08:00 ET

BioDrain Presents Growing Sales Outlook at the National Investment Banking Association Conference in Boston

Outlook Analysis Attached

MINNEAPOLIS, MN--(Marketwire - Aug 22, 2011) - BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, today announced that Alan Shuler, the Company's Secretary and Acting Chief Financial Officer, presented additional details of the Company's growing sales outlook at the National Investment Banking Association (NIBA) Conference that was held at the Omni Parker House in Boston on August 17-19, 2011.

Addressing an audience of more than 70 investors on August 18, Mr. Shuler included a newly updated activity report describing the rapidly expanding sales opportunities for BioDrain's unique, patented, FDA approved Streamway System. The report, which was included as a slide in the Company's investor presentation and included below within this release, identifies near-term opportunities from hospitals across the nation with sales potential of over $3 million and long-term opportunities representing sales potential of over $7 million. These figures derive from potential orders for Streamway System units recently identified by our newly expanded sales rep team and the expected recurring revenues from consumables that accrue to each unit. (Hospitals are identified here according to location only.)

"I was excited to present our latest developments in commercializing BioDrain's Streamway System to NIBA's audience of investment banking, corporate finance and investment brokerage firms," declared Mr. Shuler. "Our newly expanded sales rep force is aggressively increasing our ability to demonstrate Streamway's continuous, automated and cost effective process to an expanding number of hospitals and surgical centers. As these medical centers discover the safety, low cost, improved environmental impact and efficiency of the Streamway System, we anticipate a corresponding conversion of these demonstrations into purchase orders, and we are preparing to meet the demand. The additional slide to our investor presentation provides an overview of the opportunities that are now in our sales pipeline."

About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).

BioDrain's Streamway System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's Streamway System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit:

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8-K filings.


Account Name # of systems for first order Potential Additional OR's Rank System Amount first order Annual Consumable Revenue, first order Potential Add'l System Amount same hospital Potential Add'l Annual Consum-
Northern Midwest Hospital 1 12 1 1 24,000 168,000 144,000
Northern Midwest Hospital - Birthing 1 0 1 12,565 15,000 - -
Midwest Health Center 2 0 1 27,000 25,000 - -
Northern Midwest Hospital - Imaging 1 0 1 12,565 10,000 - -
East Coast Health System 5 0 1 89,750 60,000 - -
Minnesota Surgery Center 1 3 1 1 15,000 42,000 36,000
California Children's Hospital 3 13 1 45,000 30,000 182,000 156,000
South Florida Surgery Center 15 0 2 210,000 180,000 - -
East Coast Medical Center 4 18 2 48,000 40,000 252,000 216,000
South Central Medical Center 1 6 2 14,000 12,000 84,000 72,000
Midwest Medical Center 5 0 2 54,000 50,000 - -
Northern Midwest Medical Center 1 7 2 1 18,000 98,000 84,000
Northern Midwest Medical Center 4 0 2 45,000 40,000 - -
Northern Midwest Medical Center 1 0 2 1 10,000 - -
California Children's Hospital 2 0 2 30,000 20,000 - -
Northern Midwest Medical Center 2 8 2 20,000 25,000 112,000 96,000
Southern California Surgery Center 2 0 2 34,700 32,000 - -
East Coast Hospital 2 12 2 28,500 16,000 168,000 144,000
Northern Midwest Surgery Center 2 3 2 30,000 20,000 42,000 36,000
South Florida Surgery Center 7 0 2 72,000 150,000 - -
Midwest Hospital 20 50 3 300,000 250,000 700,000 600,000
Northern Midwest Hospital - Imaging 1 15 3 1 10,000 210,000 180,000
Northern Midwest Hospital 33 10 3 330,000 396,000 140,000 120,000
Northern Midwest Hospital 1 15 3 14,000 12,000 210,000 180,000
Midwest Endoscopy Center 5 0 3 75,000 50,000 - -
122 172 1,492,085 1,510,000 2,408,000 2,064,000

Total Identified + Potential Units 294
Total Identified Units + Consumables Revenues , for first order $ 3,002,085
Total Potential Units + Consumables Revenues , same hospital $ 4,472,000

1 = Purchase Order, or verbal commitment received for purchase.
2 = High level of interest expressed, working through demo / purchasing process.
3 = initial discussions with preliminary interest expressed.
The $1 accounts would either be reference accounts or lead ins to additional significant purchases, once the account is familiar with the System.
Rep Groups Additional States Covered
Pacific West Medical 7
Crown Medical 6

Contact Information

  • Investor Relations Contact:
    Stanley Wunderlich
    Consulting for Strategic Growth 1 Ltd.
    Tel: 800-625-2236 ext. 7770
    Email: Email Contact